AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Glancy Prongay & Murray LLP Announces Investigation on Behalf of Acorda Therapeutics, Inc. Investors (ACOR)

March 6, 2019

LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) --

Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR ) investors concerning the Company and its directors’ and officers’ possible violations of state laws.

If you purchased Acorda Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244 or Garth Spencer, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at gspencer@glancylaw.com or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

ContactsGlancy Prongay & Murray LLPLesley Portnoy, 310-201-9150 or 888-773-9224Garth Spencer, 212-682-5340 gspencer@glancylaw.comwww.glancylaw.com